Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 165,064 shares of the company’s stock after acquiring an additional 6,300 shares during the period. Johnson & Johnson makes up about 1.8% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 5th largest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Johnson & Johnson were worth $20,029,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. TT International increased its holdings in shares of Johnson & Johnson by 254.1% during the first quarter. TT International now owns 136,518 shares of the company’s stock valued at $15,930,000 after acquiring an additional 97,969 shares in the last quarter. Eagle Global Advisors LLC increased its holdings in Johnson & Johnson by 1.6% in the 1st quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock worth $9,927,000 after buying an additional 1,221 shares during the period. Chilton Capital Management LLC increased its holdings in Johnson & Johnson by 23.6% in the 1st quarter. Chilton Capital Management LLC now owns 95,055 shares of the company’s stock worth $12,181,000 after buying an additional 18,122 shares during the period. LPL Financial LLC increased its holdings in Johnson & Johnson by 9.7% in the 1st quarter. LPL Financial LLC now owns 957,508 shares of the company’s stock worth $122,705,000 after buying an additional 84,855 shares during the period. Finally, Great West Life Assurance Co. Can increased its holdings in Johnson & Johnson by 1.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,784,116 shares of the company’s stock worth $485,495,000 after buying an additional 72,159 shares during the period. Institutional investors and hedge funds own 66.67% of the company’s stock.
Shares of NYSE:JNJ traded up $0.03 during midday trading on Friday, reaching $133.87. 6,853,988 shares of the company’s stock were exchanged, compared to its average volume of 6,952,697. The company has a market capitalization of $370.70 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 2.19 and a beta of 0.70. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. The company had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. Johnson & Johnson’s revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.83 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.
In related news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Company insiders own 0.22% of the company’s stock.
Several equities analysts recently weighed in on JNJ shares. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Sanford C. Bernstein assumed coverage on Johnson & Johnson in a research report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price on the stock. Credit Suisse Group set a $151.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Friday, July 13th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $143.91.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: NASDAQ Stock Market Explained
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.